e75 peptide an immunogenic peptide from the HER2 protein - antimicrobial-peptides-mode-of-action E75 has been used to target cancers in several formulations Understanding the E75 Peptide: A Key Player in Cancer Vaccine Development

ole-henriksen-peptide-lip-treatment-strawberry-sorbet The e75 peptide has emerged as a significant component in the ongoing research and development of cancer vaccines, particularly for breast cancer and prostate cancer. This immunogenic peptide, derived from the HER2 protein, holds promise due to its ability to stimulate a targeted immune response against cancer cells that overexpress this protein. The HER2/neu (E75) Peptide is a specific sequence, often referred to as nelipepimut-S, that has been extensively studied for its therapeutic potential.The E75 HER2/neu peptide vaccine

Expertise and Experience in E75 Peptide Research

The extensive body of research surrounding the e75 peptide underscores the expertise and experience in this field作者：EA Mittendorf·2014·被引用次数：294—E75(nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenicpeptidederived from the HER2 protein. We have conducted phase I/II .... Numerous studies, including those by GT Clifton, EA Mittendorf, JP Holmes, and EJ Schneble, have contributed to our understanding of its properties and applications. These researchers have explored its use in various formulations, most notably as a peptide vaccine. The consistent citation of these works highlights their foundational role in advancing e75 peptide research. For instance, Mittendorf's work in 2008, cited 131 times, details how the e75 peptide (specifically HER2/neu 369-377) is an immunogenic peptide from the HER2/neu protein that is overexpressed in many breast cancer patients. Similarly, Holmes's research in 2008 investigated the optimal dose and schedule of an HER-2/neu (E75) peptide vaccine, administered with granulocyte–macrophage colony-stimulating factor (GM-CSF).

E75 Peptide as a Targeted Cancer Therapy

The primary mechanism behind the e75 peptide's therapeutic potential lies in its immunogenicity.Clinical and immunologic effects of a HER2/neu (E75) ... It is an immunogenic peptide derived from the HER2 protein, meaning it can trigger an immune response.The development and use of the E75 (HER2 369-377) ... Specifically, the e75 peptide is a nine-amino-acid-long polypeptide derived from the HER-2 receptorNelipepimut S - SELLAS Life Sciences Group - AdisInsight. It is known to bind to the HLA-A2 molecule, a critical step in activating cytotoxic T lymphocytes (CTLs)Long-term follow-up assessment of a HER-2/neu peptide .... These CTLs are crucial for identifying and destroying cancer cells that exhibit the HER2 protein on their surface.Application of HER2 peptide vaccines in patients with breast ... This targeted approach makes the e75 peptide a valuable candidate for developing personalized mRNA vaccines and other advanced cancer treatment strategies.

Clinical Trials and Applications of the E75 Peptide

The e75 peptide has been evaluated in numerous clinical trials, primarily focusing on its safety and efficacy as a vaccine. Studies have assessed the safety and documented local and systemic toxicity to the peptide vaccine (E75) in patients with node-negative breast cancer. These trials aim to determine the optimal dose and schedule for its administration.作者：MT Hueman·2005·被引用次数：62—Abstract Purpose:The E75 peptide isan immunogenic peptide from the HER-2/neu proteinthat is sub- stantially expressed in prostate cancer. For example, a phase I/II clinical trial of the E75 vaccine, as reported by Mittendorf in 2014, involved patients with HER2-positive breast cancer. Another study revealed that Nelipepimut-S (E75) was a nine-amino-acid peptide extracted from the HER2 protein capable of increasing patient survival rates.

The e75 peptide is recognized as the most frequently studied anti-HER2 vaccination strategy for the treatment of breast cancer. Beyond breast cancer, its application extends to prostate cancer, where it has been investigated as an immunogenic peptide from the HER2/neu protein that is substantially expressed. The E75 and GP2 vaccines are noted as among the few therapeutic vaccines currently under clinical research targeting HER2 in breast cancer patients作者：EJ Schneble·2014·被引用次数：91—Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer. The NeuVax™ ( .... Furthermore, research is exploring advanced formulations, such as a long multi-epitope peptide E75-AE36 encapsulated in nanoliposomes, which could serve as an effective multi-epitope vaccine.

The e75 peptide is also available for research purposes, with suppliers offering the HER2/neu (E75) Peptide made to order, providing a CoA with HPLC and MS data to ensure quality and reproducibility in experiments measuring levels or activity.作者：Z You·2021·被引用次数：41—TheE75and GP2 vaccines are the few therapeutic vaccines targeting HER2 currently under clinical research for patients with breast cancer. The E75, Her-2/neu (369-377) (E-PP-1077) is one such product used for studying these parametersE75, Her-2/neu (369-377) (E-PP-1077).

Future Directions and Broader Implications

The ongoing development of peptide-based breast cancer vaccines demonstrates the continued optimism surrounding the e75 peptide. While early trials have shown promise, research is continually refining its applicationOptimal dose and schedule of an HER-2/neu (E75) peptide .... The development of an effective peptide-based vaccine for COVID-19 and the exploration of personalized mRNA vaccines for cancer treatment signal a broader shift towards precision medicine, where peptides like e75 play a crucial roleFirst-in-human clinical trial of personalized, biomaterial-based .... The potential for long-term follow-up assessment of a HER-2/neu peptide vaccine in high-risk prostate cancer patients further underscores its versatility2023年12月15日—Nelipepimut S, was a cancer vaccine based onE75, an extracellular domainpeptideof the HER-2/neu protein that was being developed by .... The e75 peptide represents a significant advancement in the quest for more effective and targeted cancer therapies.